HEART FAILURE WITH REDUCED EJECTION FRACTION

This phase 3 trial studies 1,200 people with severe coronary artery disease and a weak heart pump (ejection fraction 40% or less). Participants are randomly assigned to receive either guideline-directed medical therapy, bypass surgery, or stenting. The study tracks survival, hear…

This study tests whether a ketone ester supplement, taken three times a day for 12 weeks, can improve heart function in people with heart failure. Fifty participants will be randomly assigned to receive the supplement or a placebo. Heart function will be measured using cardiac MR…

This study tests a new device that creates a small passage in the heart to relieve pressure, without leaving a permanent implant. It is for 350 people with heart failure and reduced pumping ability. The goal is to see if it reduces deaths, need for a heart pump or transplant, and…

This study tests a new device that combines two heart therapies: one to strengthen heartbeats and another to stop dangerous rhythms. About 300 adults with heart failure and a weak heart pump will get the device. Researchers will check if it safely converts life-threatening heart …

This Phase 2 trial tests JK07, a lab-made protein designed to help heart cells repair and pump better. About 282 adults with chronic heart failure will receive either JK07 or a placebo. The study looks at safety and whether JK07 can improve heart function in two groups: those wit…

This study tests whether a special heart pacing technique (left bundle branch pacing) combined with standard heart failure drugs can improve heart function better than drugs alone. It includes 50 adults with non-ischemic heart failure and a specific heart block. The main goal is …

This study is a large registry that will follow 5,000 people with heart failure who have received a Barostim implant. The goal is to see how well the device works in everyday medical practice to improve symptoms and quality of life. Participants are already implanted and will be …

This study looks at how vericiguat, a recently approved heart failure drug, improves heart function during activity and at rest. Researchers will give 30 adults with heart failure either vericiguat or a placebo for about three months, then measure heart performance using catheter…

This early study tests a device that creates a small opening between the upper chambers of the heart to relieve pressure in people with symptomatic heart failure. The study includes 71 participants and focuses on safety and whether the device works as intended. It is not a cure b…

This early study tests a device that creates a small, temporary opening in the wall of the heart to relieve pressure and improve symptoms in people with advanced heart failure. The main goal is to see if the procedure is safe. About 20 participants who have not responded well to …

This study tests whether a ketone drink can improve exercise ability in people with heart failure. Researchers will give 25 participants either the drink or a placebo before exercise tests. The goal is to see if the drink helps them exercise longer and with less shortness of brea…

This study tests whether a 9-month program that encourages people with heart failure to gradually increase their daily steps and walking speed can improve their physical function and symptoms. Two hundred participants will either receive standard care or the step-based program, w…

This study uses healthcare claims data from nearly 24,000 people to see if it can reproduce the results of the EMPEROR-Reduced trial, which tested the diabetes drug empagliflozin against sitagliptin in heart failure patients. The goal is not to test a new treatment, but to learn …

This study tests a redesigned clinical decision support tool for heart failure patients during virtual visits. The tool gives doctors medication recommendations and tips for patients to upload their vitals at home. Researchers will compare it to the usual tool in a small pilot wi…

This study tests a new computer tool that gives doctors personalized reminders when prescribing heart failure medications. The goal is to help doctors follow treatment guidelines more closely. About 764 doctors from cardiology and primary care clinics are taking part.

This trial aimed to see if an AI program could help doctors choose better heart failure treatments for each patient. It planned to compare standard care with AI-generated treatment advice. However, the study was withdrawn before enrolling any participants, so no results are avail…

This study looks at whether standard blood tests for heart failure show different results in African American and Caucasian patients. Researchers will compare levels of cardiac biomarkers in 400 adults newly diagnosed with heart failure. The goal is to see if current tests miss o…

This study looks at 500 adults in Romania with heart failure with reduced ejection fraction who are taking Entresto. Researchers will use existing medical records to see if patients are also receiving other recommended medications like beta-blockers and SGLT2 inhibitors. The goal…

This study tests whether sending cardiologists regular emails about quality goals helps them prescribe recommended medications for heart failure and atrial fibrillation. Researchers will track prescribing rates for 7,000 patients. The goal is to see if simple feedback can improve…

This study looks at tiny RNA molecules in the blood of 200 people hospitalized with acute congestive heart failure. Researchers want to see if these RNA levels change as patients receive decongestive therapy and if they can help predict who will respond well to treatment. The goa…